NKTR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NKTR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nektar Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for Nektar Therapeutics's Piotroski F-Score or its related term are showing as below:
During the past 13 years, the highest Piotroski F-Score of Nektar Therapeutics was 8. The lowest was 1. And the median was 3.
The historical data trend for Nektar Therapeutics's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nektar Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Piotroski F-Score | Get a 7-Day Free Trial | 3.00 | 4.00 | 1.00 | 4.00 | 2.00 |
Nektar Therapeutics Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Piotroski F-Score | Get a 7-Day Free Trial | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 |
For the Biotechnology subindustry, Nektar Therapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Nektar Therapeutics's Piotroski F-Score falls into.
How is the Piotroski F-Score calculated?
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun24) TTM: | Last Year (Jun23) TTM: |
Net Income was -45.837 + -42.079 + -36.802 + -52.363 = $-177.08 Mil. Cash Flow from Operations was -42.121 + -47.047 + -47.888 + -37.702 = $-174.76 Mil. Revenue was 24.144 + 23.885 + 21.639 + 23.489 = $93.16 Mil. Gross Profit was 11.713 + 16.602 + 13.105 + 13.749 = $55.17 Mil. Average Total Assets from the begining of this year (Jun23) to the end of this year (Jun24) was (494.279 + 442.244 + 398.033 + 396.012 + 343.334) / 5 = $414.7804 Mil. Total Assets at the begining of this year (Jun23) was $494.28 Mil. Long-Term Debt & Capital Lease Obligation was $90.76 Mil. Total Current Assets was $295.19 Mil. Total Current Liabilities was $57.33 Mil. |
Net Income was -59.049 + -59.688 + -137.018 + -51.122 = $-306.88 Mil. Revenue was 23.625 + 22.023 + 21.594 + 20.499 = $87.74 Mil. Gross Profit was 18.653 + 15.79 + 14.534 + 13.505 = $62.48 Mil. Average Total Assets from the begining of last year (Jun22) to the end of last year (Jun23) was (861.987 + 781.006 + 710.6 + 561.743 + 494.279) / 5 = $681.923 Mil. Total Assets at the begining of last year (Jun22) was $861.99 Mil. Long-Term Debt & Capital Lease Obligation was $105.82 Mil. Total Current Assets was $441.06 Mil. Total Current Liabilities was $50.69 Mil. |
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nektar Therapeutics's current Net Income (TTM) was -177.08.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Nektar Therapeutics's current Cash Flow from Operations (TTM) was -174.76.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Score 1 if it's higher, 0 if it's lower.
ROA (This Year) | = | Net Income | / | Total Assets (Jun23) |
= | -177.081 | / | 494.279 | |
= | -0.35826122 |
ROA (Last Year) | = | Net Income | / | Total Assets (Jun22) |
= | -306.877 | / | 861.987 | |
= | -0.35601117 |
Nektar Therapeutics's return on assets of this year was -0.35826122. Nektar Therapeutics's return on assets of last year was -0.35601117.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Score 1 if CFROA > ROA, 0 if CFROA <= ROA.
Nektar Therapeutics's current Net Income (TTM) was -177.08. Nektar Therapeutics's current Cash Flow from Operations (TTM) was -174.76.
==> -174.76 > -177.08 ==> CFROA > ROA ==> Score 1.
Funding
Question 5. Change in Gearing or Leverage
Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.
Score 0 if this year's gearing is higher, 1 otherwise.
Gearing (This Year: Jun24) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun23 to Jun24 |
= | 90.763 | / | 414.7804 | |
= | 0.21882182 |
Gearing (Last Year: Jun23) | = | Long-Term Debt & Capital Lease Obligation | / | Average Total Assets from Jun22 to Jun23 |
= | 105.817 | / | 681.923 | |
= | 0.15517441 |
Nektar Therapeutics's gearing of this year was 0.21882182. Nektar Therapeutics's gearing of last year was 0.15517441.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Current Ratio (This Year: Jun24) | = | Total Current Assets | / | Total Current Liabilities |
= | 295.188 | / | 57.326 | |
= | 5.14928654 |
Current Ratio (Last Year: Jun23) | = | Total Current Assets | / | Total Current Liabilities |
= | 441.058 | / | 50.694 | |
= | 8.70039847 |
Nektar Therapeutics's current ratio of this year was 5.14928654. Nektar Therapeutics's current ratio of last year was 8.70039847.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Nektar Therapeutics's number of shares in issue this year was 208.828. Nektar Therapeutics's number of shares in issue last year was 189.656.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Gross Margin (This Year: TTM) | = | Gross Profit | / | Revenue |
= | 55.169 | / | 93.157 | |
= | 0.59221529 |
Gross Margin (Last Year: TTM) | = | Gross Profit | / | Revenue |
= | 62.482 | / | 87.741 | |
= | 0.71211862 |
Nektar Therapeutics's gross margin of this year was 0.59221529. Nektar Therapeutics's gross margin of last year was 0.71211862.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Asset Turnover (This Year) | = | Revenue | / | Total Assets at the Beginning of This Year (Jun23) |
= | 93.157 | / | 494.279 | |
= | 0.18847048 |
Asset Turnover (Last Year) | = | Revenue | / | Total Assets at the Beginning of Last Year (Jun22) |
= | 87.741 | / | 861.987 | |
= | 0.10178924 |
Nektar Therapeutics's asset turnover of this year was 0.18847048. Nektar Therapeutics's asset turnover of last year was 0.10178924.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score | = | Que. 1 | + | Que. 2 | + | Que. 3 | + | Que. 4 | + | Que. 5 | + | Que. 6 | + | Que. 7 | + | Que. 8 | + | Que. 9 |
= | 0 | + | 0 | + | 0 | + | 1 | + | 0 | + | 0 | + | 0 | + | 0 | + | 1 | |
= | 2 |
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Nektar Therapeutics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
Nektar Therapeutics (NAS:NKTR) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Thank you for viewing the detailed overview of Nektar Therapeutics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.
Howard W Robin | director, officer: President & CEO | |
Jonathan Zalevsky | officer: Chief R&D Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Mark Andrew Wilson | officer: SVP & General Counsel | 1613 RAY DRIVE, BURLINGAME CA 94010 |
Robert Chess | director, officer: Executive Chairman | |
Myriam Curet | director | 1020 KIFER ROAD, SUNNYVALE CA 94086 |
Jeffrey Robert Ajer | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Sandra A. Gardiner | officer: Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Jillian B. Thomsen | officer: VP & Chief Accounting Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Karin Eastham | director | C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037 |
Gil M Labrucherie | officer: SVP, COO & CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
John Northcott | officer: SVP & Chief Commercial Officer | 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158 |
Diana Brainard | director | C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
R Scott Greer | director | 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253 |
Lutz Lingnau | director | 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945 |
Stephen K Doberstein | officer: Chief Scientific Officer | 129 ELSIE STREET, SAN FRANCISCO CA 94110 |
From GuruFocus
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By GuruFocus Research • 03-05-2024
By PRNewswire • 08-08-2024
By GuruFocus Research • 03-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.